Sentences with phrase «ovarian cancer patients»

Researchers looked at tissue samples from ovarian cancer patients.

«Niraparib significantly improves outcome of ovarian cancer patients in landmark trial.»

The targeted therapy rucaparib, which has demonstrated robust clinical activity in ovarian cancer patients with a BRCA mutation, also showed promise in previously treated pancreatic cancer patients with the mutation, according to results from a phase II clinical study.

PARP inhibitors are offering new treatment options for ovarian cancer patients with known mutations, but early - stage diagnosis is still elusive.

«New imaging technique could identify additional ovarian tumors not visible to surgeons» eyes: Amount of residual tumor left after surgery is an important prognostic factor for ovarian cancer patient survival.»

The newly approved drug would target about 15 to 20 percent of ovarian cancer patients who have the specific gene mutation, known as deleterious BRCA.

In addition to being a member of CRI's Clinical Leadership Committee, Dr. Coukos is currently the lead investigator of a CRI - funded clinical trial that is treating ovarian cancer patients with two immunotherapies — MEDI4736, an anti-PD-L1 checkpoint inhibitor, and motolimod, a TLR8 agonist.

«Overexpression of one of the lncRNAs, DNM30S, was significantly correlated with worse overall ovarian cancer patient survival,» said Dr. Eischen.

The trial, conducted in advanced ovarian cancer patients, was a pilot trial aimed primarily at determining safety and feasibility, but there were clear signs that it could be effective: About half of the vaccinated patients showed signs of anti-tumor T - cell responses, and those «responders» tended to live much longer without tumor progression than those who didn't respond.

Metastatic ovarian cancer patients treated with chemotherapy prior to surgery had altered immune cells in their tumors, and specific alterations identified suggest that immunotherapy given after chemotherapy may help in preventing the cancer from coming back, reports Frances R. Balkwill, PhD, professor of cancer biology at Barts Cancer Institute in Queen Mary University of London, United Kingdom.

However, immune checkpoint blockade therapies [such as pembrolizumab and nivolumab] can stop this from happening, so we suggest that immune checkpoint blockade might be a suitable form of immunotherapy to give to ovarian cancer patients after chemotherapy,» she added.

TRINOVA - 1 was a randomized prospective phase III clinical trial that added trebananib or placebo to standard chemotherapy (weekly paclitaxel) among 919 women with recurrent ovarian cancer patient from 179 sites in 32 countries.

«New test could detect ovarian cancer patients who are strongly responding to treatment.»

Dr James Brenton, one of the lead authors of the study at the University of Cambridge, said: «There's a need for a test to find out quickly whether ovarian cancer patients are benefiting from chemotherapy.

Scientists might be able to quickly predict how ovarian cancer patients are likely to respond to chemotherapy treatment using a simple blood test, according to a Cancer Research UK - funded study published in PLOS Medicine.

«This aligns with what we see in the clinic, that newly - diagnosed ovarian cancer patients most often already have widespread disease,» says Velculescu.

Based on these results, two phase 3 trials are being planned for platinum - sensitive and platinum - resistant ovarian cancer patients by one of NCI's new National Cancer Trial Network Groups, the NRG Oncology Group (formerly 3 cooperative groups: the National Surgical Adjuvant Breast and Bowel Project (NSABP), the Radiation Therapy Oncology Group (RTOG), and the Gynecologic Oncology Group (GOG).

A study of serous carcinoma cells (above) from ovarian cancer patients found extra or missing copies of many genes.

Next, we performed preclinical microPET imaging studies using ovarian cancer patient — derived xenografts in mouse models.

Platinum - sensitive ovarian cancer patients with a positive predictive AGO score who undergo a secondary debulking surgery after relapse on platinum chemotherapy experience longer progression - free survival.

Cancer Network presents exclusive coverage on ovarian cancer from the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting, with reports on the latest clinical research changing the way ovarian cancer patients are being managed and treated.

Olaparib is a PARP inhibitor, which is already used to treat certain ovarian cancer patients and prevents damaged cancer cells from repairing themselves after chemotherapy or radiotherapy.

«Our study suggests a therapeutic benefit for repurposing a well - tolerated inhibitor with limited toxicity to treat a specific group of ovarian cancer patients with high levels of CARM1 expression,» said Sergey Karakashev, Ph.D., first author of the study and a postdoctoral researcher in the Zhang Lab.

They embedded cephalexin — marketed as Keflexa and Keftaba — in a polymer containing tin and tested it against two cell lines, both obtained from ovarian cancer patients who had not responded to conventional chemotherapy.

Dr. Odunsi has made significant research contributions, which include the characterization of tumor antigens and then using them to develop immunotherapy vaccines for ovarian cancer patients.

A newly devised tumor - specific fluorescent agent and imaging system guided surgeons in real time to remove additional tumors in ovarian cancer patients that were not visible without fluorescence or could not be felt during surgery, reports Alexander L. Vahrmeijer MD, PhD, head of the Image - guided Surgery group in the Department of Surgery at Leiden University Medical Center in the Netherlands.

During the study period, the Roswell Park scientists enrolled a total of 68 ovarian cancer patients with NY - ESO -1-positive tumors to cancer vaccine trials targeting NY - ESO - 1.

«Based on these findings our lab is exploring several different strategies to understand and target LKB1 and its related molecules in ovarian cancer spheroids, and developing the essential pre-clinical models to see if this can be translated to ovarian cancer patients.»

«Ovarian cancer patients may benefit from pelvic radiotherapy.»

By evaluating the molecular changes that occur in large cohorts of ovarian cancer patients, the researchers were able to identify several lncRNAs that are linked to the disease.

Its authors point out that in 60 to 85 per cent of ovarian cancer patients, relapse will occur after initial treatment.

Studies have shown that ovarian cancer patients have a better chance of survival if they are referred to a specialized gynaecological cancer unit, but this only happens for a minority of women in Europe and the US at present.

«Once the ovarian cancer becomes drug resistant we can not cure it,» says Rodriguez a gynecologic oncologist who provides treatment to ovarian cancer patients and is director of the precision medicine initiative at Rutgers Cancer Institute of New Jersey.

«The current options for maintenance therapy in the EU are bevacizumab, which can only be given once and improves progression - free survival by just a few months, and the PARP inhibitor olaparib, which is only approved in patients with a germline BRCA mutation (about 10 - 15 % of ovarian cancer patients).

Niraparib significantly improved all endpoints across a broad patient population representing 70 % of all ovarian cancer patients.

Though smaller in number, some patients with advanced disease and carrying a BRCA mutation may benefit from the same targeted therapy being used today in the clinic to successfully treat some ovarian cancer patients.»

Notably, the researchers found that, using their methods, highly reactive TILs could be obtained from some 90 % of the ovarian cancer patients whose tumor samples they examined.

Their Stories, Kat Barrell never imagined that someday she would share her own story as an ovarian cancer patient.

Together, these and other findings strongly suggest that immunotherapies that can induce or enhance optimal immunologic conditions within ovarian cancers may hold great promise for extending the lives of ovarian cancer patients.

The clinical course of ovarian cancer patients is marked by periods of remission and relapse of sequentially shortening duration until chemotherapy resistance develops.

In the proposed project, Dr. Lampi Hermanson will produce NK cells from stem cells, inserting a chimeric antigen receptor (CAR) with the capacity to recognize mesothelin cells, which is expressed in 70 % of ovarian cancer patients.

[4] Sabbatini P, Tsuji T, Ferran L, Ritter E, Sedrak C, Tuballes K, Jungbluth AA, Ritter G, Aghajanian C, Bell - McGuinn K, Hensley ML, Konner J, Tew W, Spriggs DR, Hoffman EW, Venhaus R, Pan L, Salazar AM, Diefenbach CM, Old LJ, Gnjatic S. Phase I trial of overlapping long peptides from a tumor self - antigen and poly - ICLC shows rapid induction of integrated immune response in ovarian cancer patients.

The targeted antibody bevacizumab (Avastin ®) is already approved for ovarian cancer patients, and a number of immune - based therapies are being investigated in early - phase clinical trials for patients with ovarian cancer.

This page features information on ovarian cancer and immunotherapy clinical trials for ovarian cancer patients, and highlights the Cancer Research Institute's role in working to bring effective immune - based cancer treatments to ovarian cancer patients.

Whether that will be restricted to patients with a homologous recombination deficiency or all ovarian cancer patients is probably going to depend on the particular combination.